Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline
Identifieur interne : 000B88 ( Main/Exploration ); précédent : 000B87; suivant : 000B89Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline
Auteurs : M. F. Mccarty [États-Unis]Source :
- Medical Hypotheses [ 0306-9877 ] ; 1997.
Abstract
Increased plasma levels of fibrinogen and C-reactive protein (CRP), as well as leukocytosis, are now established as risk factors for the thromboembolic complications of vascular disease. Chronic inflammation or infection associated with an acute-phase response – notably, periodontal disease and smoking-induced lung damage – are likewise known to increase cardiovascular risk. A common etiologic factor in these conditions may be interleukin-6 (IL-6), acting on hepatocytes to induce acute-phase reactants that increase blood viscosity and promote thrombus formation. Recent evidence that hypertrophied adipocytes release IL-6, and that hyperglycemia evokes IL-6 production by endothelium, may explain why plasma fibrinogen is increased in visceral obesity and poorly controlled diabetes. IL-6 is released by a range of tissues in response to stimulation by the monocyte-derived cytokines interleukin-1 and tumor necrosis factor; by suppressing production of these cytokines, fish oil, α-linolenic acid, and pentoxifylline can reduce IL-6 synthesis. Moderate ethanol consumption, as well as sex-hormone replacement, also appear to inhibit IL-6 production or activity. These practical protective measures may be of particular value to patients with pre-existing atheroma and elevated plasma levels of acute-phase reactants. Since IL-6 plays a crucial physiological role in osteoclast generation and activation, these measures may also aid preservation of bone density.
Url:
DOI: 10.1054/mehy.1997.0684
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline</title><author><name sortKey="Mccarty, M F" sort="Mccarty, M F" uniqKey="Mccarty M" first="M. F." last="Mccarty">M. F. Mccarty</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DB0FC3571F59C53993217EACE3025FD1B552DE5B</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1054/mehy.1997.0684</idno><idno type="url">https://api.istex.fr/document/DB0FC3571F59C53993217EACE3025FD1B552DE5B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A42</idno><idno type="wicri:Area/Main/Curation">000A30</idno><idno type="wicri:Area/Main/Exploration">000B88</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Exploration">000B88</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline</title><author><name sortKey="Mccarty, M F" sort="Mccarty, M F" uniqKey="Mccarty M" first="M. F." last="Mccarty">M. F. Mccarty</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>NutriGuard Research, 1051 Hermes Avenue, Encinitas, CA 92024</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Medical Hypotheses</title><title level="j" type="abbrev">YMEHY</title><idno type="ISSN">0306-9877</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">52</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="465">465</biblScope><biblScope unit="page" to="477">477</biblScope></imprint><idno type="ISSN">0306-9877</idno></series><idno type="istex">DB0FC3571F59C53993217EACE3025FD1B552DE5B</idno><idno type="DOI">10.1054/mehy.1997.0684</idno><idno type="PII">S0306-9877(97)90684-8</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0306-9877</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Increased plasma levels of fibrinogen and C-reactive protein (CRP), as well as leukocytosis, are now established as risk factors for the thromboembolic complications of vascular disease. Chronic inflammation or infection associated with an acute-phase response – notably, periodontal disease and smoking-induced lung damage – are likewise known to increase cardiovascular risk. A common etiologic factor in these conditions may be interleukin-6 (IL-6), acting on hepatocytes to induce acute-phase reactants that increase blood viscosity and promote thrombus formation. Recent evidence that hypertrophied adipocytes release IL-6, and that hyperglycemia evokes IL-6 production by endothelium, may explain why plasma fibrinogen is increased in visceral obesity and poorly controlled diabetes. IL-6 is released by a range of tissues in response to stimulation by the monocyte-derived cytokines interleukin-1 and tumor necrosis factor; by suppressing production of these cytokines, fish oil, α-linolenic acid, and pentoxifylline can reduce IL-6 synthesis. Moderate ethanol consumption, as well as sex-hormone replacement, also appear to inhibit IL-6 production or activity. These practical protective measures may be of particular value to patients with pre-existing atheroma and elevated plasma levels of acute-phase reactants. Since IL-6 plays a crucial physiological role in osteoclast generation and activation, these measures may also aid preservation of bone density.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Mccarty, M F" sort="Mccarty, M F" uniqKey="Mccarty M" first="M. F." last="Mccarty">M. F. Mccarty</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/SchutzV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B88 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B88 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= SchutzV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DB0FC3571F59C53993217EACE3025FD1B552DE5B
|texte= Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline
}}
| This area was generated with Dilib version V0.6.38. |  |